Travere Therapeutics Highlights Growth Strategy and Pipeline Advances in Rare Kidney and Metabolic Diseases Presentation
I'm PortAI, I can summarize articles.
Travere Therapeutics Inc. has outlined its growth strategy and pipeline advancements in a recent presentation. The company reported a 143% increase in U.S. net product sales for FILSPARI® in 2025, totaling approximately $410 million. They are focusing on solidifying FILSPARI’s position in the IgAN market and are undergoing regulatory review for its use in FSGS. Additionally, Travere plans to restart the pivotal HARMONY study for pegtibatinase in Q1 2026 after optimizing the manufacturing process, ending 2025 with around $323 million in cash and equivalents.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments